



BEYOND INSULIN: EXPLORING NON-HORMONAL THERAPEUTIC PATHWAYS FOR TYPE 1 DIABETES MANAGEMENT

Govind¹, Pooja Sinoriya², Aditya Mathur², Pooja³, Arti Sinoria⁴, Tina Bhardwaj^{2*}

¹SGT College of Pharmacy, SGT University, Gurugram, Haryana 122505

²B.M. College of Pharmacy, Farukhnagar, Gurugram, Haryana 122506

³World College of Pharmaceutical Sciences, Girawar, Jhajjar, Haryana 124103

⁴Goel Institute of Pharmacy and Sciences, Lucknow, Uttar Pradesh 226028

***Corresponding Author:** Mrs. Tina Bhardwaj

Associate Professor, B.M. College of Pharmacy, Farukhnagar, Gurugram, Haryana 122506

Email: tina070490@gmail.com

ABSTRACT

Type 1 diabetes (T1DM) is an autoimmune disorder distinguished by the T cell-mediated destruction of pancreatic beta cells that produce insulin, which leads to inadequate insulin synthesis and hyperglycemia. Even though traditional insulin therapy is necessary, its drawbacks make it necessary to investigate non-hormonal therapeutic approaches.

This review aims to evaluate non-hormonal therapeutic approaches for T1D management, focusing on immunomodulatory strategies, beta-cell preservation and regeneration, the role of gut microbiota interventions, and emerging bioengineered pancreatic technologies.

This review synthesizes immunomodulatory strategies which may include T-cell modulation, cytokine targeting, and regulatory T-cell enhancement, suppressing autoimmunity while stabilizing residual beta-cell function. Among regenerative medicine tools will be stem cell therapy, gene therapy, and encapsulated islet transplantation in an attempt to restore endogenous insulin production. Although Probiotics, prebiotics, and intervening metabolomics will open new doors for T1D prevention through the natural involvement of the gut microbiome in immune modulation. Advances in bioengineered pancreas technologies involve combining artificial devices with cell-based therapies for improved glycemic control.

There are more adjunctive pharmacological agents such as SGLT2 inhibitors, metformin, and anti-inflammatories that can add to the benefits of insulin-free glucose regulation together with protection for beta cells. There is so much promise in development, yet it seems to be a long way off for these new therapies from becoming clinical realities.

Future research should be directed toward safety, efficacy, and integrating with existing treatment protocols. A multi-faceted immunomodulatory, regenerative medicine, and metabolic intervention approach may yet create the ultimate cure for T1D.

Keywords: Type 1 Diabetes, Immunomodulation, Beta-Cell Regeneration, Gut Microbiome, Artificial Pancreas

1. INTRODUCTION

Transforming the paradigm of T1D management has been opening up research on non-hormonal therapeutic approaches. While necessary, insulin therapy may not be sufficient if coupled with complementary approaches targeting immune, metabolic and regenerative pathways. Future treatments could thus be more effective and long-lasting. Instead of managing the symptoms of T1D, the therapeutic approaches will deal with the very roots of the disease. The future of diabetes care and outcomes for patients could become transformed (Akil et al., 2021; ElSayed et al., 2023). Understanding the stages of presymptomatic T1D opens doors for timely intervention and possibly prevention (Insel et al., 2015).

Overview of Type 1 Diabetes (T1D) as an Autoimmune Disease

Type 1 diabetes (T1D) is a chronic immunity-destroying condition that results from the insidious destruction of insulin-secreting pancreatic beta cells. Its genetic predisposition is overwhelmed by an overt environmental force, which launches an autoimmunological response giving rise to insulin deficiency and hyperglycemia, that is, increases in blood glucose (Grattoni et al., 2024). T1D, in contrast to type 2 diabetes, which is primarily dictated by insulin resistance, is an immune-mediated disease wherein autoreactive T-cells attack pancreatic beta cells, thereby destroying the cells in their path (Todd, 2020; Van Belle et al., 2011; Atkison & Eisenbarth., 2001).

Genetic susceptibility is thus a focal point in the pathogenesis of T1D—such as the human leukocyte antigen (HLA) class II genes being the most important factors in T1D pathogenesis. Some HLA haplotypes, such as HLA-DR3/DR4, are associated with increased risk for developing the condition, while others can protect against the disease (Pociot & Lernmark, 2016). Interestingly, cases of T1D have occurred even in individuals with hereditary B-cell deficiency, underscoring the dominant role of T-cell autoimmunity (Martin et al., 2001). It is, however, evident that T1D is not solely initiated by genetically predisposing factors but that some environmental triggers (Yau & Danska, 2024), such as viral infection, changes in gut microbiota composition, and dietary components, are also implicated either in triggering or modulating the immune response (Hansen et al. 2024; Knip & Simell., 2012). Diabetogenic enteroviruses are considered one of the viral triggers potentially contributing to beta-cell destruction, and their replication may be inhibited by agents like Vemurafenib (Butrym et al., 2024).

In the autoimmunity propagation, both the innate and adaptive immune systems are active. Dendritic cells and macrophages present beta-cell antigens to autoreactive CD4⁺ and CD8⁺ T-cells, ensuing an inflammatory cascade culminating in beta-cell apoptosis (Lehuen et al., 2019). The fall-in-beta cells proceeds towards complete insulin insufficiency that impels the necessity of exogenous insulin for survival (Lin et al., 2025). Recent insights have deepened understanding of the immunological interplay between beta-cells and autoreactive immune cells (Roy et al., 2007). Perhaps, the best-known autoreactive process is where B-cells produce autoantibodies directed against beta-cell antigenic targets such as insulin, glutamic acid decarboxylase (GAD), and zinc transporter 8 (ZnT8), which are all markers for the diagnosis of T1D (Wenzlau et al., 2007).

Limitations of Insulin Therapy

Insulin therapy serves as the cornerstone of T1D management but is far from perfect, with numerous limitations preventing optimal control of the disease and the enhancement of patient quality of life. One major barricade is achieving physiological regulation of insulin; the exogenous administration of insulin cannot closely replicate physiological levels of insulin under normal conditions; with additional inputs leading to odd rises or falls of blood glucose in a day (Hölzen et al., 2024). The fluctuations result in hyperglycemia, which adds to other long-term complications such as retinopathy, nephropathy, and neuropathy, and hypoglycemia that can sometimes be life-threatening (DiMeglio et al., 2018). In addition, insulin therapy does not cure T1D's autoimmune destruction through its pathology. While insulin replacement can help survive the individual, it is not able to stop continued immunologic destruction of any residual beta cells, which limits further endogenous insulin production even in the early stage of the disease (Bluestone et al., 2010). Moreover, the

long-term use of insulin has been proposed to render patients obese and insulin-resistant, aggravating yet another layer of complexity in managing diabetes (Minges et al., 2021; Garg, 2011). Insulin therapy thus imposes another considerable hindrance upon patients. The requirement for multiple daily injections or continuous subcutaneous insulin infusion (CSII) via insulin pumps, coupled with frequent blood glucose monitoring, impacts the quality of life for individuals with T1D enormously (Foster et al., 2019). Even with the advent of continuous glucose monitoring (CGM) and hybrid closed-loop systems, insulin therapy still lacks behind with its shortcomings of requiring diligent management and patient adherence (Sherr et al., 2022; Tauschmann & Hovorka, 2018). Furthermore, a pressing issue concerning the economic burden of insulin therapy exists. It remains expensive in many countries, making it unreachable for a sizable number of patients, especially in low- and middle-income regions (Hirsch, 2016; Lan et al., 2023). The increasing cost of insulin has resulted in rationing of insulin, with serious health consequences, including diabetic ketoacidosis (Wang et al., 2020). In light of these constraints, there is an increasing realization to search for non-hormonal therapeutic alternatives that address the T1D roots instead of exogenous insulin dependence.

Rationale for Exploring Non-Hormonal Therapeutic Strategies

Limitations of insulin therapy have provoked interest in alternative therapeutic agents for T1D management or cure. Targeted immune dysregulation nonhormonal therapeutics would preserve or regenerate beta cells and modulate glucose homeostasis, hence lowering or eliminating exogenous insulin requirement (Uniyal et al., 2025). All of this will lead to improved disease outcome and quality of life for the patient. Recent reviews have emphasized the potential of novel treatment modalities in T1D, including emerging immunotherapies, microbiome modulation, and regeneration approaches (Salama et al., 2024).

Immunomodulation holds much promise too for therapy, where the immune response is changed toward preventing or delaying the destruction of beta cells. Several approaches for T-cell targeting, cytokine modulation, and antigen-specific immunotherapy are presently under investigation, all with the common aim of inducing immune tolerance and thus halting the autoimmunity progression (Nagy et al., 2022; Long et al., 2012). Examples of such approaches include monoclonal antibodies targeting CD3 (Keymeulen et al., 2021), CD20, and IL-2, whose efficacy regarding a minor preservation of beta-cell function are shown to mitigate or delay the insurgence of T1D (Bluestone et al., 2010; Fiorina et al., 2008; Herold et al., 2019).

Yet another major area of research is the preservation and regeneration of beta cells. The advances in stem cell therapy, gene therapy, replacement of beta cells with encapsulated islet cells (Leao et al., 2024), and many more have all provided hope for restoring the endogenous production of insulin for those suffering from T1D (Zarei, 2024; Hunckler & Gracia., 2020). Such developments would immunoprotect any remaining beta cells from immune destruction and engender new functional beta cells that secrete insulin (Hunault & Hesselson, 2024).

It has also been studied as a very important component in T1D pathology and treatment: the gut microbiome. Gut dysbiosis is argued to be one of the factors that contribute to tolerogenic immune dysregulation and metabolic dysfunctions in T1D (Blok et al., 2025; Murri et al., 2023). Where probiotics-prebiotics treatment and metabolomics-guided therapy are changing gut microbiome composition toward enhancing immune tolerance (Calabrese et al., 2021; Vatanen et al., 2018). Recent advances in microbiome research highlight its dual role in modulating immune responses and glycemic control, offering novel clinical applications (Zhao et al., 2021).

But though there is an overwhelming enthusiasm of late regarding add-on therapy in T1D for metabolic modulators such as sodium-glucose co-transporter 2 (SGLT2) inhibitors and metformin, such agents can also enhance glucose regulation through insulin-independent mechanisms (Najafipour et al., 2024; Mathieu et al., 2020), thus providing an extra layer of glycemic control without risk of hypoglycemia (Fattah & Vallon, 2018; Boeder & Edelman., 2019). Attempts are made with antioxidants and anti-inflammatories to reduce oxidative stress and chronic inflammation, both accused of reducing beta-cell function and events driving the disease (Herold et

al., 2024). Meta-analysis also suggests SGLT2 inhibitors carry a measurable risk of diabetic ketoacidosis (Monami et al., 2017; Musso et al., 2020; Liu et al., 2025). An international consensus further outlines strategies for minimizing DKA risk in patients using SGLT2 inhibitors (Danne et al., 2019). Metformin has also shown improvement in vascular health and insulin sensitivity in adolescents with T1D (Bjornstad et al., 2018).

Scope and Objectives of the Review

Reviews alternative non-hormonal therapeutic approaches available to Type 1 Diabetes (T1D) patients in conjunction with standard insulin therapy; these include immunomodulatory approaches for the modification of immune responses paired with destruction of beta-cells, methods of beta-cell preservation and regeneration, and the contribution of gut microflora to diet-induced metabolism. Besides, it will address the nascent technologies to include bioengineered pancreatic substitutes and adjunct pharmacotherapy for insulin independence with glucose control. The review provides recent advances and their putative advantages, disadvantages, and the potential translational prospects of such approaches into the clinic. Hence, this review provides an overall perspective on future approaches in T1D management, given its emphasis on such approaches.

Objectives of the Study:

1. To evaluate immunomodulatory approaches for T1D management.
2. To explore beta-cell preservation and regeneration strategies.
3. To analyze the role of gut microbiota and metabolic modulators in T1D.
4. To assess the potential of adjunctive and bioengineered therapies.

2. PATHOPHYSIOLOGY OF TYPE 1 DIABETES

Autoimmune Destruction of Pancreatic Beta Cells

It is an autoimmune disease in which pancreatic beta cells are selectively destroyed and absolute insulin deficiency occurs. T-cells mediated by autoantigen will adopt beta-cell antigens as nonself and initiate an immune response against them (Bluestone et al., 2010). The destruction usually occurs slowly and often starts years prior to the clinical manifestations of hyperglycemia. During this phase, the beta-cell mass continues to decline until insulin levels can no longer be maintained at homeostasis levels to normalize glucose levels (Grattoni et al., 2024). Recent molecular studies also suggest roles for microRNAs such as miR-101-3p in the Pathophysiology of T1D (Santos et al., 2019).

Genetics and environment have a large role in autoimmune destruction of these beta cells. Genetic predisposition largely includes human leukocyte antigens associated with autoimmune diseases, most notably HLA-DR3 and HLA-DR4 that are found in ~90% of T1D cases (Pociot & Lernmark, 2016). But, triggers such as viral infections (enteroviruses), imbalance in gut microbiota, and early nutrition such as cow's milk proteins are also significant for the autoimmune pathway instigation (Hansen et al., 2024).

Insulinitis is the hallmark T1D pathology, which mainly involves immune cell infiltration in pancreatic islets. Histopathological studies of pancreatic tissues from patients with T1D have revealed a dense infiltration of CD4⁺ and CD8⁺ T-cells, B-cells, macrophages, and dendritic cells in and around the islets of Langerhans. CD8⁺ T-cells are particularly important in the destruction of beta-cells by inducing cell death through cytotoxic mechanisms such as releasing perforin and granzyme. The B-cells, on the other hand, are part of the autoimmune response and produce autoantibodies against such beta-cell antigens as insulin, glutamic acid decarboxylase (GAD65), and zinc transporter 8 (ZnT8) (Wenzlau et al., 2007). These are critical biomarkers essential for the differentiation diagnosis of T1D (Lin et al., 2025). Chronic hyperglycemia results when insulin secretion is no longer adequate to overcome the damage done to beta cells. The main defect in type 2 diabetes is insulin resistance; whereas in T1D, there is an absolute deficiency of insulin requiring exogenous insulin for life (DiMeglio et al., 2018). From the beta-cell destruction, this is purely a


progressive and irreversible mechanism regarding diet intervention in protecting or mobilizing beta-cell function, as discussed further in the later sections.

Role of the Immune System in Disease Progression

It is an autoimmune disease in which pancreatic beta cells are selectively destroyed and absolute insulin deficiency occurs (Bluestone et al., 2010). T-cells mediated by autoantigen will adopt beta-cell antigens as nonself and initiate an immune response against them (Bluestone et al., 2010). The destruction usually occurs slowly and often starts years prior to the clinical manifestations of hyperglycemia. During this phase, the beta-cell mass continues to decline until insulin levels can no longer be maintained at homeostasis levels to normalize glucose levels (Grattoni et al., 2024). Genetics and environment have a large role in autoimmune destruction of these beta cells. Genetic predisposition largely includes human leukocyte antigens associated with autoimmune diseases, most notably HLA-DR3 and HLA-DR4 that are found in ~90% of T1D cases (Pociot & Lernmark, 2016). But, triggers such as viral infections (enteroviruses), imbalance in gut microbiota, and early nutrition such as cow's milk proteins are also significant for the autoimmune pathway instigation (Hansen et al., 2024). Insulinitis is the hallmark T1D pathology, which mainly involves immune cell infiltration in pancreatic islets. Histopathological studies of pancreatic tissues from patients with T1D have revealed a dense infiltration of CD4⁺ and CD8⁺ T-cells, B-cells, macrophages, and dendritic cells in and around the islets of Langerhans. CD8⁺ T-cells are particularly important in the destruction of beta-cells by inducing cell death through cytotoxic mechanisms such as releasing perforin and granzyme. The B-cells, on the other hand, are part of the autoimmune response and produce autoantibodies against such beta-cell antigens as insulin, glutamic acid decarboxylase (GAD65), and zinc transporter 8 (ZnT8). These are critical biomarkers essential for the differentiation diagnosis of T1D (Lin et al., 2025). Chronic hyperglycemia results when insulin secretion is no longer adequate to overcome the damage done to beta cells. The main defect in type 2 diabetes is insulin resistance; whereas in T1D, there is an absolute deficiency of insulin requiring exogenous insulin for life (DiMeglio et al., 2018). From the beta-cell destruction, this is purely a progressive and irreversible mechanism regarding diet intervention in protecting or mobilizing beta-cell function, as discussed further in the later sections. (Lehuen et al., 2019).

Several key immune pathways involved in T1D progression have been identified, including:

Immune Component	Role in T1D Pathogenesis
CD8⁺ T-cells	Directly induce beta-cell apoptosis via cytotoxic granules (e.g., perforin, granzyme B).
CD4⁺ T-cells	Activate CD8 ⁺ T-cells and B-cells, secrete pro-inflammatory cytokines.
Regulatory T-cells (Tregs)	Suppress autoreactive T-cells; impaired function in T1D.
B-cells	Produce autoantibodies against beta-cell antigens; contribute to antigen presentation.
Macrophages & Dendritic Cells	Present beta-cell antigens, secrete inflammatory cytokines.
Cytokines (IL-1β, IFN-γ, TNF-α)	Promote inflammation, beta-cell apoptosis, and immune cell activation.



(Figure 1: Immune Component)

Further, molecular mimicry also pertains to the autoimmune attack in T1D whereby viral or dietary antigens mimic beta-cell antigens, inducing cross-reactive immune responses (Blok et al., 2025). For instance, enterovirus infections may lead to stress on beta cells while increasing expression of MHC class I, rendering these cells vulnerable to immune attack, and trigger T1D (Calabrese et al., 2021).

Challenges in Glucose Homeostasis Beyond Insulin Deficiency

Although insulin deficiency constitutes the major pathological state in T1D, several other metabolic defects contribute to an impaired glucose homeostasis. Not only loss in beta-cell function disturbs release of insulin, but also secretion of glucagon and amylin, which critically regulate glucose in homeostasis, is affected (Fattah & Vallon, 2018).

During fasting states, glucagon secreted by pancreatic alpha cells stimulates hepatic glucose production. In turn, glucagon secretion becomes dysregulated in T1D, where inappropriate hepatic glucose output occurs even in the presence of hyperglycemia (Herold et al., 2024). In fact, this paradoxical glucagon response favors postprandial hyperglycemia and raises the risk of diabetic ketoacidosis (DKA), an endangering complication representing excessive ketone body production with metabolic acidosis (Akil et al., 2021).

Amylin is co-secreted with insulin, and it is another critical loss in T1D that promotes slow gastric emptying and inhibited postprandial glucagon secretion. Amylin deficiency in T1D leads to rapid gastric emptying, increased postprandial glucose peaks and excitement of appetite, adding to stress regarding glycemic control (Zarei et al., 2024; Antoio-Villa et al., 2021).

Insulin-independent pathways that include glucose uptake by skeletal muscle and liver are also dysfunctional in T1D. Such chronic hyperglycemia heralds oxidative stress and inflammation, resulting into endothelial dysfunction, impaired glucose uptake, and high insulin resistance (Uniyal et al., 2025). All these metabolic derangements add to the chronic complications of T1D including cardiovascular disease, neuropathy and nephropathy.

Such problems only serve to illustrate the essential need for remedial measures besides simple insulin therapy to obtain control of glucose homeostasis. Accordingly, adjunct therapies such as sodium-glucose co-transporter 2 (SGLT2) inhibitors, glucagon receptor antagonists, and amylin analogs are very promising in their capability to improve glycemic control but not cause additional hypoglycemia risk (Fattah & Vallon, 2018).

3. IMMUNOMODULATORY APPROACHES

T-Cell Targeted Therapies

The pathology of Type 1 Diabetes T1D is because of autoimmune destruction of pancreatic beta cells, mainly mediated by autoreactive T-cells. Hence, the strategies aimed at sucking to inside these T-cell activities can turn out to be very good methods to reverse the sickened condition or rescue beta-cell function. The monoclonal antibodies selectively depleting or modulating autoreactive T-cell activity have been widely explored. An example is anti-CD3 monoclonal antibodies, which have been shown to prevent or delay the onset of T1D in the high-risk individuals for developing this disease (Orban et al., 2011). CD3 is one of the most primary components of T cell receptor complex, and blocking it inhibits T cell activation and proliferation of these autoreactive T-cells while promoting immune tolerance without inducing generalized immunosuppression (Bluestone et al., 2010).

Initial clinical investigations of newly diagnosed T1D patients treated with anti-CD3 demonstrate a very promising perspective for such a therapy in conserving beta-cell function. It decreases the number of autoreactive T-cells in circulation and supports functional regulatory T-cell (Treg) functions (Gourand et al., 2022). It may slow or stop altogether the already work processes in autoimmune mode against beta cells and delay insulin therapy through this highly selective modulation of immune responses. The long-term sequelae and hazards of such therapy have yet to be assessed because, unfortunately, immune suppression usually predisposes individuals to infections. (Roep et al., 2021).

Regulatory T-Cell (Treg) Enhancement Strategies

T regulatory cells (Tregs) are the most important component of immune tolerance maintenance and autoimmunity prevention. The Treg function is compromised in T1D, leading to the loss of tolerance against pancreatic beta cells and increased autoimmune activity. As a result, augmentation of Treg function has emerged as one attractive strategy toward restoration of immune tolerance in T1D (Chhabra et al., 2021).

Methods of enhancing Treg activity have included the usage of interleukin 2 (IL-2), promoting expansion and survival of Tregs. Several low-dose IL-2 trials are underway in T1D, most showing an increase in Tregs with some evidence of improved autoimmune regulation (Zhang et al., 2024). Cytokine manipulation or gene editing approaches that expand a Treg population in vivo hits another target. For example, Foxp3, the optional master transcription factor of Treg differentiation, was shown to recover Treg function and inhibit autoimmune destruction of beta cells in preclinical models (Vignali et al., 2008).

Thus, although very promising preclinical results exist, activities for Treg enhancement must still be translated into safe and efficacious therapies for T1D patients. Alongside ensuring that long-term efficacy possibility of unwanted immunogenicity and off-target effects should be thoroughly evaluated in clinical trials before broad application. (Lehuen et al., 2019).

Cytokine Modulation (IL-2, Anti-CD3, Anti-CD20)

Now, either using a better vocabulary or suggestive sentences, there are many jargons to improve their aforementioned scientific perception. One such example is the activity of these cytokines: They are already known very well for their functions in regulation of immune responses or in ensuring the preservation or destruction of beta cells, including IL-2, IL-10, and TNF- α . Apart from all these, IL-2 is mooted having more important immunological effect in that it can induce expansion of regulatory T cells besides retarding activity of effector T cells (Blaine et al., 2015).

Monoclonal antibodies targeting CD3 (anti-CD3) show potential in early-stage trials in addition to IL-2. For instance, it has been observed that anti-CD3 antibodies such as teplizumab inhibit the activation of autoreactive T-cells and favor the induction of immune tolerance in T1D patients (Orban et al., 2011; Kokori et al., 2024). More recently, the depletion of B-cells by anti-CD20 monoclonal antibodies has induced a report of their possible utility as therapeutic agents, since B-

cells are important in antigen presentation and in the initiation of autoimmune responses (Al-Hawary et al., 2024).

There are several advantages of cytokines over conventional immunosuppressants. Most obviously, one obtains more focused interventions with narrower toxicity margins. The effects of time will have to be considered more thoroughly for their immune-related, long-term consequences and the potential for sustaining immunological tolerance where appropriate (Gouirand et al., 2022).

Role of Antigen-Specific Immunotherapy

Antigen-specific immunotherapy is a targeted therapeutic approach for T1D by induce specific immune tolerance to beta-cell antigens without global immunosuppression. Development of such strategies utilizes peptides derived from beta-cell autoantigens (GAD65, proinsulin or insulin) to stimulate such immune responses promoting tolerance rather than inflammatory activation. The concept behind antigen-specific immunotherapy rests on retraining the immune system to accept self-antigens as innocuous, and therefore, autoreactive T-cells will not be activated. Some of the early clinical trials have being very positive; especially, in patients who are newly diagnosed with T1D. For example, it has been demonstrated that low doses of either GAD65 or proinsulin peptides could partially restore beta-cell function and decrease insulin requirement (Devendra et al., 2004). The real challenge, however, will be to establish optimal dosing and delivery strategies to induce tolerance without anaphylactic reaction or other adverse effects.

Such an approach can also be synergistically applied together with other modalities including anti-CD activities or Treg-enhancing strategies. The study is ongoing on the trials of personalizing peptide-based vaccines to these patient populations with the aim of making it a safe and effective way of achieving immune tolerance toward beta-cell antigens.


Most isolates in isolated areas have all the member impeding the potential of biases influenced by other effects. Antigen-specific immunotherapy is a highly targeted therapeutic approach by which T1D is treated by re-establishing immune tolerance for beta-cell antigens without general immune suppression. Immunotherapy will use peptides derived from beta-cell autoantigens such as GAD65, proinsulin, or insulin, which initiate an immune response promoting tolerance instead of inflammation.

The principle in antigen-specific immunotherapy is that it retrains the immune system into thinking that self-antigens are harmless and failure to trigger autoreactive T-cells. Early clinical trials have yielded some results, particularly for patients newly diagnosed with T1D. For instance, giving low doses of GAD65 or proinsulin peptides partially restores beta-cell function and reduces insulin requirements (Devendra et al., 2004). However, the challenge will probably be around finding optimal dosing and delivery strategies that induce tolerance without eliciting anaphylactic reactions or other side effects.

This implies that such an approach may well be combined with other potential therapies such as anti-CD3, or Treg-enhancing strategies to achieve synergistic effects. Ongoing trials are testing the application of personalized peptide-based vaccines with the goal of providing a safe and effective means to induce immune tolerance specifically toward beta-cell antigens (Kreiner et al., 2021).

Table 1: Overview of Immunomodulatory Therapies in Type 1 Diabetes

Therapy	Mechanism of Action	Potential Outcomes
Anti-CD3 Therapy	Modulates T-cell activation	Reduces autoimmune destruction of beta cells
IL-2 Therapy	Enhances Treg expansion	Restores immune tolerance
Anti-CD20 Therapy	Depletes B-cells	Reduces autoantibody production and antigen presentation
Antigen-Specific Immunotherapy	Induces immune tolerance to beta-cell antigens	Restores tolerance without generalized immune suppression



(Figure 2: Immunomodulatory Therapies)

4. BETA-CELL PRESERVATION AND REGENERATION

Stem Cell Therapy and Islet Regeneration

Preservation of Beta-cell has emerged as a promising therapeutic strategy, aiming to halt further autoimmune destruction while supporting endogenous insulin production (Taneera & Saber-Ayad., 2024). Within the T1D scenario, the promise of stem cell therapy to regenerate beta cells is a major area of interest. Their goal is to generate functional beta cells, through the use of pluripotent stem cells (PSCs) or induced pluripotent stem cells (iPSCs), for subsequent transplantation into T1D patients to restore insulin production. Here the aim is to use stem cells to create new beta cells that can replace those destroyed through the autoimmune process to potentially cure T1D (Zhao et al., 2009).

Preclinical miniature organisms have demonstrated that beta cells generated from stem cells can produce insulin in response to glucose; thus, it would appear that this strategy may be quite feasible (Wu & Mahato, 2014; Millman et al., 2016). There have been some positive results from clinical trials using different types of stem cell therapies for T1D, including islet transplantation and encapsulated stem cells; however, other major challenges include immune rejection, limited supplies of cells, and tumor formation (Zarei et al., 2024; Mesples et al., 2013). Cell-based therapies are now advancing beyond experimental stages and are being prepared for clinical translation (Wang et al., 2025).

The gene editing of stem cells in a pre-differentiation stage into beta cells offers the potential for enhanced long-term survival and functionality of transplanted beta cells through the avoidance of immune destruction. An immediate example of how this could be carried out would include the use of the CRISPR/Cas9 method (Wu & Mahato, 2014).

Beta-Cell Replacement Strategies (e.g., Encapsulated Islet Cells)

Islet cell transplantation started to be counted among beta-cell replacement strategies for T1D. Islet transplantation means the transplantation of isolated pancreatic islets collected from deceased donors into the recipient's liver, where they immediately begin to produce insulin. This therapy has been successful in some patients; however, availability of qualified donor organs and lifelong immunosuppressive therapy to prevent rejection remain serious constraints (Hatipoglu et al., 2005). Because of these limitations, an interest has arisen for encapsulation technologies to protect the transplanted islet cells from immune attack. Encapsulation is a means where islet cells are enclosed by a biocompatible membrane that allows nutrients and insulin to diffuse in and out while

preventing immune cells from attacking the transplanted cells. Currently, several encapsulation devices such as Viacyte and Beta-O2 are in clinical trials and have shown promising results in early trials, such as insulin independence in some patients (Hatipoglu et al., 2005). Stems cells are also being explored as a source for bioprinting pancreatic tissue such as the bionic pancreases, offering futuristic replacement options (Wszola et al., 2021).

Swathes of progress have been made in the field of replacement with encapsulated islet cells regarding massive potential for solving immune rejection of transplanted cells (Zhang et al., 2022). Optimization of encapsulant materials and longer-term study of the efficacy and functionality of transplanted cells need to be done (Desai & Shea, 2017).

Gene Therapy for Beta-Cell Function Restoration

Coming from a therapeutic view, gene therapy is to some extent a novel avenue towards the restoration of beta-cell function in T1D which includes repairing or replacing disrupted beta cells or even inducing other cells to take up beta cell-like functions through direct modification of the genome of an individual's cells. A potential method would be by delivering genes using appropriate gene delivery systems for inducing either regeneration of beta cells or protection from autoimmune destruction. For instance, the introduction of genes that cause insulin production into the liver other target tissues has been shown to confer some degree of insulin independence in animal models (Alzhanuly & Sharipov, 2024).

CRISPR-Cas9-type gene editing techniques could also be used for modification of the genetic material of existing beta cells such that they are more resistant to immune attacks or to induce further proliferation of insulin producing cells from other non-endocrine tissues (Alzhanuly & Sharipov, 2024). These methods are giving hope for addressing the immune rejection barriers and limited number of cells available which inhibit beta-cell transplantation treatment.

Nonetheless, gene therapy for T1D is still in its nascent stages as issues such as delivery efficiency, off-target effects, and long-term safety have to be solved for any widespread clinical application (Zarei et al., 2024). Additionally, targeted delivery systems such as nanocarriers are being developed to improve the specificity and effectiveness of beta-cell directed therapies (Collins & Farnsworth., 2025).

Table 2: Beta-Cell Replacement and Regeneration Strategies

Strategy	Mechanism	Challenges
Stem Cell Therapy	Differentiation of stem cells into insulin-producing beta cells	Immune rejection, tumorigenesis, limited supply
Islet Transplantation	Transplantation of pancreatic islets into the liver	Donor shortage, immune rejection, immunosuppression
Encapsulated Islet Cells	Enclosure of islet cells in biocompatible membranes	Long-term efficacy, immune evasion, device complications
Gene Therapy	Genetic modification of cells to restore beta-cell function	Gene delivery challenges, off-target effects

5. GUT MICROBIOME AND METABOLIC MODULATION

Impact of Gut Microbiota on Immune Regulation and Glucose Metabolism

If dysbiosis can be defined as an alteration of gut microbiota intended to interfere with the immune system and glucose metabolism, and then indeed gut microbiota figures into the T1D pathogenesis. Some alterations in microbial communities have, according to several studies, triggered immune responses that are antagonistic to pancreatic beta cells. This has also been the case for *Bacteroides fragilis*, whereby through the generation of Tregs, tolerance is induced, thus preventing autoimmune attacks on pancreatic islets (Blok et al., 2025). In a similar fashion, newly diagnosed individuals with T1D appear to have increased richness and abundance in *Lactobacillus* and *Bifidobacterium* species of low diversity, likely indicating protection by these species (Murri et al., 2013).

Short-chain fatty acids include butyrate, propionate, and acetate, produced by gut microbes and now known to be active modulators of immune functions. By enhancing the intestinal barrier, butyrate reduces the entry of microbial antigens into peripheral tissues, where they may induce autoimmunity (De Groot et al., 2017). SCFAs modulate glucose homeostasis by enhancing the insulin sensitivity of peripheral tissue and by reducing systemic inflammation (Arpaia et al., 2013).

Probiotics and Prebiotics in T1D Management

As adjunct help in managing T1D, probiotics and prebiotics have gathered immense interest for their abilities not just to restore gut microbiota balance, but also to modify immune responses. Probiotics are live microorganisms that have health benefits and have shown protection in experimental and clinical studies. For instance, *Lactobacillus rhamnosus* GG could decrease intestinal permeability and inflammatory biomarkers in persons at risk of developing T1D when consumed (Ho et al, 2021). *Bifidobacterium breve* has a similar source; in fact, it protects the beta cells from destruction by increasing anti-inflammatory cytokine production (Vaarala et al., 2017). Non-digestible fibers that in fact stimulate the growth of gut probiotics act in immune modulation as well. In addition to that, inulin-type fructans and GOS are capable of enhancing the production of SCFA, thus promoting differentiation of Tregs which denies the pro-inflammatory response (Sivaprakasam et al., 2016; Marino et al., 2017). The co-administration of pre-and probiotics (synbiotics) can improve the promised increase in gut microbial diversity to affect glycemic modulation in T1D animal models. (Roesch et al., 2018).


Metabolomics-Driven Therapeutic Strategies

Metabolomics-the study of small-molecule metabolites within biological systems-explains certain inside information being revealed regarding the pathogenesis of type 1 diabetes and gives fresh insights into potential therapeutic avenues. Specific metabolic signatures linked to T1D have recently been established, including amino acids and lipid profiles (Pociot & Lernmark, 2016). For example, lower levels of tryptophan and its metabolites have been associated with diminished Treg function with resultant predisposition toward autoimmunity (Sonner et al., 2019).

Novel metabolome-based therapeutic work is seeking to modulate some of those metabolic pathways to prevent or delay T1D disease manifestation. In this setting, one of the most promising methods is the use of nicotinamide, a precursor of NAD⁺, which is protective for beta cells against oxidative stress and inflammation (Gale, 2018). Likewise, omega-3 fatty acids with anti-inflammatory properties have been proposed for possible use as metabolic modulators in T1D (Calder, 2017).

Table 3: Key Biomaterials for Beta-Cell Encapsulation

Material	Properties	Application
Alginate	Biocompatible, immune-shielding	Beta-cell encapsulation
PEG	Controlled drug release, enhanced survival	Artificial islet transplantation
Hydrogel		
Chitosan	Antimicrobial, promotes vascularization	Scaffold for pancreatic tissue engineering



(Figure 3: Key Biomaterials for Beta-Cell Encapsulation)

6. ARTIFICIAL AND BIOENGINEERED PANCREAS TECHNOLOGIES

Role of Bioengineered Tissues in Pancreatic Function Restoration

The new approaches of bioengineering are ushering in a new era in diabetes management through the restoration of pancreatic function through tissue regeneration. One such possibility could be a bioartificial pancreas, which is composed of insulin-secreting cells encapsulated into biocompatible materials. Such encapsulated cells would protect the transplanted cells from immune assaults while allowing nutrients and insulin output in response to glucose levels to diffuse in (Vegas et al., 2016; Zhang et al., 2022).

Another way is to have functional vasculature along with bioprinted pancreas tissues. Development of 3D bioprinting has recently permitted the generation of organoids that produce insulin from stem cells, exhibiting behavior akin to the native function of the pancreas (Hunckler & García, 2020). This route is full of promise for a long-lasting insulin-independence period among patients with T1D.

Table 4: Comparison of Artificial Pancreas Technologies

Technology	Advantages	Challenges
Hybrid Closed-Loop Systems	Automated glucose control, FDA-approved	Requires frequent calibration, expensive
Fully Automated Systems	No manual intervention needed, adaptive AI	Limited availability, ongoing research
Bioartificial Pancreas	Encapsulated beta cells, immune protection	Cell viability concerns, long-term studies needed

Emerging Advancements in Implantable Pancreas Devices

An implantable artificial pancreas is an innovation for the treatment of T1D. These devices were further developed to integrate continuous glucose monitoring (CGM) systems with automated insulin delivery systems to achieve optimum blood glucose levels. The Medtronic MiniMed 670G, for example, is the first-ever hybrid closed-loop system approved by the FDA. It reportedly demonstrated improvement in glycemic maintenance and a reduced incidence of hypoglycemia in T1D patients using this device (Brown et al., 2019).

Moreover, next-generation artificial pancreas systems, which use machine-learning techniques to build adaptive algorithms for enhanced glucose regulation, will also be developed. The last-

mentioned technology with biocompatible sensors detecting immediate changes in metabolism will further improve the performance of the devices (Dovc et al., 2020). Research will be enhanced further on developing implantable biohybrid pancreatic systems composed of bioengineered islet cells and automated insulin delivery sustaining activity for an extended period.

Hybrid Approaches Integrating Non-Hormonal Strategies

Hybrid approaches that commingle bioengineering with immunomodulatory and metabolic therapies are growing interest as potential curative strategies for T1D. One such approach involves encapsulated beta-cell transplants combined with an immune-tolerance induction to prevent rejection, as stated by Rickels et al. (2018). These might also include specific immunotherapy, so that it enables long-term graft persistence without the lifelong need for immunosuppression.

In addition, there are people working on microbiota-modulating interventions together with bioengineering pancreas technology to enable improved metabolic homeostasis. Probiotic supplementation and bioartificial pancreas devices could enhance insulin sensitivity while reducing the inflammatory response (Salvador et al., 2021).

7. ADJUNCTIVE PHARMACOLOGICAL THERAPIES

SGLT2 Inhibitors for Glucose Regulation

Out of many oral antidiabetic, sodium glucose co transporter 2 inhibitors are available these days, providing avenues even to consider their application in the management of Type 1 diabetes (T1D). Some of these drugs-here empagliflozin, canagliflozin, and dapagliflozin-are effective by inhibiting the SGLT2 protein in the kidneys that reabsorbs glucose (Ma et al., 2021). Thus, one ends up increasing glucose being excreted through urine and decreasing the glucose level in the blood system (Nongthombam et al., 2025). Despite the fact that the drugs were predominant in addition to oral regimens for Type 2 Diabetes, the top studies directed at these drugs are the clinical trials that have assessed their efficacy in T1D as an adjunct to insulin therapy (Araki et al., 2021).

Several trials such as INCEPT or DEPICT have shown the glycemic lowering abilities of SGLT2 inhibitors in patients with T1D without incurring risk of hypoglycemia, as has been shown by reduction in HbA1c levels (El Masri et al., 2018; Boeder et al., 2025). Moreover, these agents impart great value in terms of cardiovascular and renal benefits, which is very useful information for this T1D population that raised their baseline risks for both cardiovascular diseases and diabetic nephropathy (Lo et al., 2020). SGLT2 inhibitors, however, can also cause adverse events such as acidemia from diabetes (DKA), urinary tract infections, and volume depletion, all of which require monitoring (Bantounou et al., 2024).

Metformin's Role in Insulin-Independent Glucose Control

Traditionally used as an oral hypoglycemic in Type 2 Diabetes, metformin is now attracting consideration as adjunctive therapy in T1DM. Its predominant action is to inhibit liver glucose production while also activating AMP-activated protein kinase (AMPK) to improve peripheral tissue insulin sensitivity (Sowa et al., 2015). It may be rationalized that the imposed enhancement of insulin resistance in T1D-an increased insulin resistance has its share in the impaired glucose control-would increase glycemic control without remarkable increases in the risk for hypoglycemia, supported by its synergistic action with metformin.

Research regarding T1D and the effects of metformin was able to cause a reduction in HbA1c levels and enhance insulin sensitivity in fair measure (Baker et al., 2021; Lund et al., 2018). Furthermore, metformin may be linked to weight-controlled factors affecting health since it in most cases causes weight gain in T1D patients on insulin but does not reduce hyperglycemia as effectively compared to insulin and is therefore useful in patients who are insulin resistant (Forner et al., 2024). It is a very rare effect, but in patients with impaired renal function, it may still trigger concern, and so periodic assessment of renal function is warranted (Cree-Green et al., 2019).

Antioxidants and Anti-Inflammatory Agents in T1D Management

Oxygen stress and inflammation acting on a humanly level play a significant role in the pathogenesis of T1D, leading to damage to pancreatic beta cells and triggering complications such as nephropathy and retinopathy through its action on beta cells. Antioxidants and other anti-inflammatory agents have opened up an exciting avenue for adjunct therapies to be designed for tackling this problem.

Many antioxidants, including alpha-lipoic acid (ALA), vitamin E, and N-acetylcysteine (NAC), have until today been investigated for their potential to modulate oxidative damage in T1D. One good example of ALA is where it has been noted that this antioxidant improves endothelial function and lowers markers for oxidative stress-the condition identified in T1D patients (Abubaker et al., 2022; Callaghan et al., 2015; Scaramuzza et al., 2015). Likewise, NAC, whose parent compound is the precursor antioxidant glutathione, has been shown to exert beneficial action in decreasing oxidative damage and enhancing beta-cell function in animal models of T1D (Baumel-Alterzon et al., 2024).

Such anti-inflammatory agents as the monoclonal antibody to TNF-alpha have been already investigated for T1D potential therapeutic agents. Infliximab is the monoclonal antibody that showed its effects in mitigating inflammation of beta cells, delaying the initiation of diabetes in animal models and improving glycaemic control in patients with T1D (dos Santos et al., 2023). So far, these agents are still being studied, and their long-term safety and effectiveness remains an uncertainty (Taneera & Saber-Ayad, 2024; Lacigova et al., 2001).

Table 5: Advantages and Challenges of Adjunctive Pharmacological Therapies in T1D

Therapy	Advantages	Challenges
SGLT2 Inhibitors	Reduces HbA1c, cardiovascular benefits, no hypoglycemia	Risk of DKA, requires monitoring, cost
Metformin	Enhances insulin sensitivity, weight control	Modest glycemic control, not effective alone
Antioxidants	Reduces oxidative stress, preserves beta-cell function	Unclear long-term safety, variable response

8. CHALLENGES AND FUTURE DIRECTIONS

Limitations of Current Non-Hormonal Therapies

While the progress related to the non-hormonal therapies for T1D, they still suffer from limitations that make it difficult to adopt them into widespread use. One major barrier is the risk of diabetic keto-acidosis (DKA), especially with the use of SGLT2 inhibitors (Musso et al., 2020; Danne et al., 2019). This risk has been a subject of concern since the occurrence of DKA among patients receiving SGLT2 inhibitors is prevalent in the case of a person known to have insulin-dependent diabetes because the absence of insulin therapy can predispose people to this very dangerous complication (Bantounou et al., 2024).

Adjuvant treatments such as metformin and antioxidants have a promising future, but they usually produce minor benefits compared with any existing insulin treatment. The lack of achievement of glycemic control like that with insulin, particularly in the case of the insulin-dependent, narrows the role of metformin in the management of T1D (Forner et al., 2024). Also, the long-term safety of these antioxidants and anti-inflammatory agents remains unknown, so the need for effectiveness and safety assessments in managing T1D still exists (Lacigova et al., 2001; George & McCrimmon., 2013; Ding et al., 2023).

The absence of internationally agreed treatment protocols is also a major challenge to non-hormonal therapy. This kind of treatment is still largely experimental and has very few clinical trials addressing issues specific to the T1D population. Additionally, most of non-hormonal therapies have not been integrated into standard clinical practice to add to the challenges since every patient does not respond the same way and needs individualized treatment plans.

Integration with Existing Treatment Protocols

It holds true that a seamless and efficient integration of non-hormonal therapies into existing insulin-based co-therapies is the vital link to improving patient outcomes. Meanwhile, the most recent protocols for T1D management mainly result in an institution of an insulin-based therapy regimen (Holt et al., 2021; Gubitosi-Klug et al., 2016), which is the corner-block of the treatment. Non-hormonal therapies have much to add to insulin treatment; most are being used, like the SGLT2 inhibitors, metformin, and antioxidants, but any of these could be complemented with better glycemic control, improvements in insulin resistance, and prevention of long-term complications (Baker et al., 2021; Cherney et al., 2014; Steffes et al., 2003). Hypertriglyceridemia, a common metabolic complication in T1D, has been associated with increased long-term cardiovascular risk (Wang et al., 2019).

Hypertriglyceridemia, a common metabolic complication in T1D, has been associated with increased long-term cardiovascular risk (Wang et al., 2019).

However, the introduction of these therapies will usually need a fine balance and adjustment of insulin doses for an individual patient. For instance, the addition of SGLT2 inhibitors will probably need some reduction in the doses of insulin to avoid hypoglycemia or DKA. Likewise, there might have to be some adjustment in insulin therapy due to the insulin-sensitizing effects of metformin so that it does not lower glucose levels too much. Therefore, it becomes increasingly important to define clearly the guidelines of co-administration of these therapies with insulin in order to ensure their safety and efficacy.

The role of personalized medicine becomes increasingly relevant when considering the application of non-hormonal treatments. The genetic and phenotypic variability among T1D subjects may also affect their responses to the therapies given as adjunct treatments; therefore, treatment plans must be tailored according to individual needs (El Masri et al., 2018).

Future Research Prospects and Clinical Translation

While hormonal therapies have improved in recent years in the management of T1D, they should now have future research efforts identifying novel mechanisms for intervention that are targeted non-hormonal therapies, such as gut microbiota modulation in T1D; the impact of the microbiome may, after all, involve both immune responses and glucose metabolism (Blok et al., 2025; Wang et al., 2025; Vatenen et al., 2018). Further research will also seek to measure the efficacy of combination therapies, such as with an SGLT2 inhibitor using immunomodulatory or metabolic therapies (Blau & Garvey, 2024; Boeder et al., 2025)

Bioengineered pancreas devices and stem cell therapies will make great advances in future T1D treatments. Restoration of pancreatic function by bioengineered tissues and organoids might decrease insulin dependency (Hunckler & García, 2020). Sophisticated artificial pancreas systems integrated with non-hormonal therapies would probably render glucose regulation more precise and effective (Hogrebe et al., 2023; Wszola et al., 2021; Tauschmann & Hovorka., 2018).

Extensive clinical trials will establish the scope of safety, efficacy, and long-term advantages for translation into clinical settings of these therapies. Now collaboration among researcher, clinician, and regulatory entity is inevitable to transferring wider populations of T1D patients into these therapeutics.

Table 6: Integration of Non-Hormonal Therapies with Insulin Protocols

Therapy	Integration Strategy	Required Adjustments
SGLT2 Inhibitors	Add to insulin therapy for enhanced glucose control	Reduce insulin doses, monitor for DKA risk
Metformin	Combine with insulin for insulin resistance management	Adjust insulin doses based on insulin sensitivity
Antioxidants	Use as adjunct to prevent complications	Monitor for efficacy in reducing inflammation

9. CONCLUSION

Summary of Key Findings

It is the one that creates anger for permanent type-1 diabetics: the autoimmune disease in which pancreatic beta cells are destroyed, leading to dependence on exogenous insulin therapy throughout life. Although it forms the foundation of treatment in T1D, insulin therapy neither treats the underlying autoimmune pathology nor halts the progression of the disease. The review examined many non-hormonal therapeutic approaches, including immunomodulation, regeneration of beta-cells, modulation of the gut microbiome, artificial pancreas technologies, and adjunctive pharmacological paradigms, all of which hold promise in revolutionizing the management of T1D.

These immunomodulatory therapies not only include T-cell targeted therapies but also therapeutic enhancement by regulatory T cells (Tregs) and modulation by cytokines to try and prevent or slow down the progressive destruction of beta-cells due to altered immune response (Todd, 2021). Interventions targeting CD3, CD20, and interleukin have been shown to delay disease onset and save residual beta-cell activity in patients diagnosed with the disease for a very short time.

Endogenous insulin production could be recreated through strategies like preservation and regeneration of beta-cells which included stem cell therapy, islet cell transplantation, and gene therapy. The progress of encapsulated islet cells and genetically modified beta cells harbors possible long-term solutions to lessen the lifelong necessity for immunosuppression.

In addition, the gut microbiome has been shown to be a vital parameter of immune modulation and metabolic health. Probiotic and prebiotic therapies and strategies that use metabolomics to tackle disease have shown promise in modulating immune responses and improving glucose homeostasis.

Innovation in bioengineered pancreas technology, such as implantable devices and hybrid approaches, points towards another way of improving glycemic control not purely but rather through insulin therapy. It is this kind of innovation that lays the foundation through advanced bioengineering for future non-hormonal therapies with next-generation treatment paradigms.

Adjunctive pharmacological therapy comprised SGLT2 inhibitors, metformin, and some antioxidants and provided further premium benefits over glucose regulation, insulin sensitivity, and protection against oxidative stress. Emerging research advocates for the role of solidarities in T1D management while reviewing treatments traditionally used in the type 2 diabetes population.

Potential Impact on T1D Management

Non-hormonal therapeutic strategies integrated into T1D services may revolutionize therapy by reduction of therapy dependency on insulin, control in glycemic values, or progression of disease (Zarei et al., 2024). Immunomodulatory therapies may halt or slow down the destruction of beta cells and possibly lead to functional cure in certain individuals. Likewise, techniques for beta-cell regeneration may restore endogenous insulin production and with it render exogenous administration unnecessary. The gut microbiome presents a therapeutic dimension unique from the other because of immunomodulation and metabolic pathway modulation. Microbiome-based intervention mechanisms when applied with metabolomic profiling could allow an individual become personalized effectively in treatment strategies with respect to that person's gut microbiota composition. Artificial pancreas technologies are alternatives to traditional pumps in the administration of insulin; rather, they involve integrating bioengineered tissues with non-hormonal approaches. These technologies will maximize the strength of independence exhibited by the patient, minimize glycemic variation in the long run, and improve health outcomes. Such adjunctive pharmacological therapies of SGLT2 inhibitors and metformin have shown worth concerning improvement in aspects such as glucose metabolism, optimized weight management, and cardiovascular health. Such combinations may be administered within immunomodulatory or regenerative therapeutic approaches toward a more holistic approach in T1D therapy.

Call for Further Research and Innovation

There is a lot to be learned and many challenges to face regarding these therapies, especially moving them to clinical application. Long-term safety assessments are prerequisites to immunomodulatory interventions for evaluating their anti-infectious or autoimmune risk propensity. There is still an

area of regenerative therapies for beta cells to be explored further in terms of extended periods of functionality and safety from immune-mediated destruction.

Research continues to delve into gut microbiome as a potential window for T1D treatment, but further work is required to study the specific microbe strains that have potential for use in therapy. Large multicenter, randomized studies will likely be needed to evaluate the effects of probiotics, prebiotics, and metabolomics interventions among diverse populations.

Engineering pancreatic technologies must be improved to afford better biocompatibility, longevity, and functionality. The thrust of research in future should be hybrid approaches that mix cell-based strategies with artificial pancreas systems to provide more holistic and robust therapies for T1D patients.

Long-term safety and any possible benefit from immunomodulatory or regenerative adjunct pharmacotherapy in T1D should be the subject of research. The personalized treatment paradigm, which is based on genomic, proteomic, and metabolomic information, would bring about precision therapeutic strategies that meet the profile of an individual patient.

Insulin provides a lifeline in T1D, so too does the non-hormonal therapeutic route provide fresh stimulus toward an even better disease outcome and quality of life. Most of the research effort needs to be converged now toward combinatorial approaches, with the realization of these advances changing experimental models into more easily and widely applicable clinical treatments. With continuous scientific innovation, interdisciplinary collaboration, and translated research, the vision of a functional cure for T1D will become closer to reality.

REFERENCES

1. Grattoni, A., Korbitt, G., Tomei, A. A., García, A. J., Pepper, A. R., Stabler, C., & de Vos, P. (2024). Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road ahead. *Nature Reviews Endocrinology*, 1-17. <https://www.nature.com/articles/s41574-024-01029-0>
2. Bluestone, J. A., Herold, K., & Eisenbarth, G. (2010). Genetics, pathogenesis and clinical interventions in type 1 diabetes. *Nature*, 464(7293), 1293-1300. <https://www.nature.com/articles/nature08933>
3. Hölzen, L., Schultes, B., Meyhöfer, S. M., & Meyhöfer, S. (2024). Hypoglycemia unawareness—a review on pathophysiology and clinical implications. *Biomedicines*, 12(2), 391. <https://www.mdpi.com/2227-9059/12/2/391>
4. Hirsch, I. B. (2016). Insulin in America: a right or a privilege? *Diabetes Spectrum*, 29(3), 130-132. <https://diabetesjournals.org/spectrum/article-abstract/29/3/130/32812>
5. Pociot, F., & Lernmark, Å. (2016). Genetic risk factors for type 1 diabetes. *The Lancet*, 387(10035), 2331-2339. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(16\)30582-7/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30582-7/abstract)
6. Uniyal, P., Panwar, S., Bhatt, A., Marianesan, A. B., Kumar, R., Singh, T. G., & Kumar, B. (2025). An update on current type 2 diabetes mellitus (T2DM) druggable targets and drugs targeting them. *Molecular Diversity*, 1-27. <https://link.springer.com/article/10.1007/s11030-025-11149-y>
7. Herold, K. C., Delong, T., Perdigoto, A. L., Biru, N., Brusko, T. M., & Walker, L. S. (2024). The immunology of type 1 diabetes. *Nature Reviews Immunology*, 24(6), 435-451. <https://www.nature.com/articles/s41577-023-00985-4>
8. Lin, T. C., Lacorcía, M., & Mannering, S. I. (2025). Current and Emerging Assays for Measuring Human T-Cell Responses Against Beta-Cell Antigens in Type 1 Diabetes. *Biomolecules*, 15(3), 384. <https://www.mdpi.com/2218-273X/15/3/384>
9. Nagy, G., Szekely, T. E., Somogyi, A., Herold, M., & Herold, Z. (2022). New therapeutic approaches for type 1 diabetes: Disease-modifying therapies. *World journal of diabetes*, 13(10), 835. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9606789/>
10. Zarei, M., Sheikholeslami, M. A., Mozaffari, M., & Mortada, Y. (2024). Innovative Immunotherapies and Emerging Treatments in Type 1 Diabetes Management. *Diabetes*

- Epidemiology and Management, 100247.
<https://www.sciencedirect.com/science/article/pii/S2666970624000519>
11. Blok, L., Hanssen, N., Nieuwdorp, M., & Rampanelli, E. (2025). From microbes to metabolites: advances in gut Microbiome research in type 1 diabetes. *Metabolites*, 15(2), 138. <https://www.mdpi.com/2218-1989/15/2/138>
 12. Calabrese, C. M., Valentini, A., & Calabrese, G. (2021). Gut microbiota and type 1 diabetes mellitus: The effect of Mediterranean diet. *Frontiers in nutrition*, 7, 612773. <https://www.frontiersin.org/articles/10.3389/fnut.2020.612773/full>
 13. Fattah, H., & Vallon, V. (2018). The potential role of SGLT2 inhibitors in the treatment of type 1 diabetes mellitus. *Drugs*, 78, 717-726. <https://link.springer.com/article/10.1007/s40265-018-0901-y>
 14. Donath, M. Y., Dinarello, C. A., & Mandrup-Poulsen, T. (2019). Targeting innate immune mediators in type 1 and type 2 diabetes. *Nature Reviews Immunology*, 19(12), 734-746. <https://www.nature.com/articles/s41577-019-0213-9>
 15. Akil, A. A. S., Yassin, E., Al-Maraghi, A., Aliyev, E., Al-Malki, K., & Fakhro, K. A. (2021). Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era. *Journal of translational medicine*, 19(1), 137. <https://link.springer.com/article/10.1186/s12967-021-02778-6>
 16. DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018). Type 1 diabetes. *The Lancet*, 391(10138), 2449-2462. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(18\)31320-5/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31320-5/abstract)
 17. Hansen, M. S., Pokharel, P., Piganelli, J., & Sussel, L. (2024). The chicken or the egg dilemma: Understanding the interplay between the immune system and the β cell in type 1 diabetes. *Cold Spring Harbor Perspectives in Medicine*, a041591. <https://perspectivesinmedicine.cshlp.org/content/early/2024/07/01/cshperspect.a041591.short>
 18. Blaine, J., Chonchol, M., & Levi, M. (2015). Renal control of calcium, phosphate, and magnesium homeostasis. *Clinical Journal of the American Society of Nephrology*, 10(7), 1257-1272. https://journals.lww.com/CJASN/fulltext/2015/07000/Renal_Control_of_Calcium_Phosphate_and_Magnesium.19.aspx
 19. Alzhanuly, B., & Sharipov, K. (2024). Latest advancements in the development of new therapies for type 1 diabetes. *Bratislava Medical Journal/Bratislavské Lekárske Listy*, 125(8). <https://search.ebscohost.com/login.aspx?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=00069248&AN=179221198&h=I9P3k0ilgA6cY8%2B3ntAzon3zxa9THvYz6bjzFJWeCyHxTnhO%2Fx7riaD7a7MSEl3R58ECdkSQnFnduK17GyAMAQ%3D%3D&crl=c>
 20. Devendra, D., Liu, E., & Eisenbarth, G. S. (2004). Type 1 diabetes: recent developments. *Bmj*, 328(7442), 750-754. <https://www.bmj.com/content/328/7442/750.short>
 21. Al-Hawary, S. I. S., Jasim, S. A., Hjaz, A., Ullah, H., Bansal, P., Deorari, M., & Abosaoda, M. K. (2024). A new perspective on therapies involving B-cell depletion in autoimmune diseases. *Molecular Biology Reports*, 51(1), 629. <https://link.springer.com/article/10.1007/s11033-024-09575-6>
 22. Gouirand, V., Habrylo, I., & Rosenblum, M. D. (2022). Regulatory T cells and inflammatory mediators in autoimmune disease. *Journal of Investigative Dermatology*, 142(3), 774-780. <https://www.sciencedirect.com/science/article/pii/S0022202X21013038>
 23. Desai, T., & Shea, L. D. (2017). Advances in islet encapsulation technologies. *Nature reviews Drug discovery*, 16(5), 338-350. <https://www.nature.com/articles/nrd.2016.232>
 24. Kreiner, F. F., von Scholten, B. J., Coppieters, K., & von Herrath, M. (2021). Current state of antigen-specific immunotherapy for type 1 diabetes. *Current Opinion in Endocrinology, Diabetes and Obesity*, 28(4), 411-418. <https://journals.lww.com/co->

- [endocrinology/fulltext/2021/08000/Current_state_of_antigen_specific_immunotherapy.13.aspx?context=LatestArticles](https://endocrinology.fulltext/2021/08000/Current_state_of_antigen_specific_immunotherapy.13.aspx?context=LatestArticles)
25. Hatipoglu, B., Benedetti, E., & Oberholzer, J. (2005). Islet transplantation: current status and future directions. *Current Diabetes Reports*, 5(4), 311-316. <https://link.springer.com/article/10.1007/s11892-005-0029-9>
26. Orban, T., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., & Skyler, J. S. (2011). Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. *The Lancet*, 378(9789), 412-419. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(11\)60886-6/fulltext?elq=ee57e9cf2dbb44439de1b398de11fe9f](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60886-6/fulltext?elq=ee57e9cf2dbb44439de1b398de11fe9f)
27. Zhang, R., Zhao, Y., Chen, X., Zhuang, Z., Li, X., & Shen, E. (2024). Low-dose IL-2 therapy in autoimmune diseases: An update review. *International Reviews of Immunology*, 43(3), 113-137. <https://www.tandfonline.com/doi/abs/10.1080/08830185.2023.2274574>
28. Roep, B. O., Thomaidou, S., Van Tienhoven, R., & Zaldumbide, A. (2021). Type 1 diabetes mellitus as a disease of the β -cell (do not blame the immune system?). *Nature Reviews Endocrinology*, 17(3), 150-161. <https://www.nature.com/articles/s41574-020-00443-4>
29. Wu, H., & Mahato, R. I. (2014). Mesenchymal stem cell-based therapy for type 1 diabetes. *Discovery medicine*, 17(93), 139-143. <http://www.discoverymedicine.com/Hao-Wu/2014/03/07/mesenchymal-stem-cell-based-therapy-for-type-1-diabetes/>
30. Vignali, D. A., Collison, L. W., & Workman, C. J. (2008). How regulatory T cells work. *Nature reviews immunology*, 8(7), 523-532. <https://www.nature.com/articles/nri2343>
31. Lo, K. B., Gul, F., Ram, P., Kluger, A. Y., Tecson, K. M., McCullough, P. A., & Rangaswami, J. (2020). The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis. *Cardiorenal Medicine*, 10(1), 1-10. <https://karger.com/crm/article/10/1/1/86567>
32. Bantounou, M. A., Sardellis, P., Thuemmler, R., Black Boada, D., Kaczmarek, J., Mahmood, R., & Philip, S. (2024). Effect of the dual sodium-glucose co-transporter-1 and-2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. *Diabetes, Obesity and Metabolism*, 26(2), 710-720. <https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.15364>
33. El Masri, D., Ghosh, S., & Jaber, L. A. (2018). Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis. *Diabetes Research and Clinical Practice*, 137, 83-92. <https://www.sciencedirect.com/science/article/pii/S016882271731344X>
34. Nongthombam, G. S., Ahmed, S. A., Saikia, K., Gogoi, S., & Borah, J. C. (2025). Breaking boundaries in diabetic nephropathy treatment: design and synthesis of novel steroidal SGLT2 inhibitors. *RSC Medicinal Chemistry*, 16(1), 296-311. <https://pubs.rsc.org/en/content/articlehtml/2025/md/d4md00645c>
35. Baker, C., Retzik-Stahr, C., Singh, V., Plomondon, R., Anderson, V., & Rasouli, N. (2021). Should metformin remain the first-line therapy for treatment of type 2 diabetes? *Therapeutic Advances in Endocrinology and Metabolism*, 12, 2042018820980225. <https://journals.sagepub.com/doi/abs/10.1177/2042018820980225>
36. Forner, P., Snaith, J., & Greenfield, J. R. (2024). Prescribing patterns of adjunctive therapy for the treatment of type 1 diabetes mellitus among Australian endocrinologists. *Internal Medicine Journal*, 54(5), 779-785. <https://onlinelibrary.wiley.com/doi/abs/10.1111/imj.16312>
37. Cree-Green, M., Bergman, B. C., Cengiz, E., Fox, L. A., Hannon, T. S., Miller, K., & Nadeau, K. J. (2019). Metformin improves peripheral insulin sensitivity in youth with type 1 diabetes. *The Journal of Clinical Endocrinology & Metabolism*, 104(8), 3265-3278. <https://academic.oup.com/jcem/article-abstract/104/8/3265/5423566>
38. Abubaker, S. A., Alonazy, A. M., Abdulrahman, A., Abubaker, S., Alonazy, A., & Albasseet, A. (2022). Effect of alpha-lipoic acid in the treatment of diabetic neuropathy: A

- systematic review. *Cureus*, 14(6). <https://www.cureus.com/articles/98939-effect-of-alpha-lipoic-acid-in-the-treatment-of-diabetic-neuropathy-a-systematic-review.pdf>
39. Baumel-Alterzon, S., Katz, L. S., Lambertini, L., Tse, I., Heidery, F., Garcia-Ocaña, A., & Scott, D. K. (2024). NRF2 is required for neonatal mouse beta cell growth by maintaining redox balance and promoting mitochondrial biogenesis and function. *Diabetologia*, 67(3), 547-560. <https://link.springer.com/article/10.1007/s00125-023-06071-7>
40. dos Santos Haber, J. F., Barbalho, S. M., Sgarbi, J. A., de Argollo Haber, R. S., de Labio, R. W., Laurindo, L. F., ... & Payão, S. L. M. (2023). The relationship between type 1 diabetes mellitus, TNF- α , and IL-10 gene expression. *Biomedicines*, 11(4), 1120. <https://www.mdpi.com/2227-9059/11/4/1120>
41. Taneera, J., & Saber-Ayad, M. M. (2024). Preservation of β -cells as a therapeutic strategy for diabetes. *Hormone and Metabolic Research*, 56(04), 261-271. <https://www.thieme-connect.com/products/ejournals/html/10.1055/a-2239-2668>
42. Hunckler, M. D., & García, A. J. (2020). Engineered biomaterials for enhanced function of insulin-secreting β -cell organoids. *Advanced Functional Materials*, 30(48), 2000134. <https://onlinelibrary.wiley.com/doi/abs/10.1002/adfm.202000134>
43. Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., ... & T1D Exchange Clinic Network. (2019). State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. *Diabetes Technology & Therapeutics*, 21(2), 66-72. <https://doi.org/10.1089/dia.2018.0384>
44. Lehuen, A., Diana, J., Zacccone, P., & Cooke, A. (2019). Immune cell crosstalk in type 1 diabetes. *Nature Reviews Immunology*, 19(11), 734–747. <https://doi.org/10.1038/s41577-019-0204-2>
45. Sherr, J. L., Heinemann, L., & Fleming, G. A. (2022). Glycemic control with hybrid closed-loop insulin delivery: Systematic review. *Diabetes Care*, 45(2), 368–378. <https://doi.org/10.2337/dci21-0024>
46. ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., & Gabbay, R. A. (2023). Introduction and methodology: standards of care in diabetes—2023. *Diabetes Care*, 46(Supplement_1), S1-S4. <https://doi.org/10.2337/dc23-Sint>
47. Insel, R. A., Dunne, J. L., Atkinson, M. A., Chiang, J. L., Dabelea, D., Gottlieb, P. A., & Ziegler, A. G. (2015). Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. *Diabetes Care*, 38(10), 1964-1974. <https://doi.org/10.2337/dc15-1419>
48. Zhao, L., Zhang, F., Ding, X., Wu, G., & Lam, K. S. (2021). Gut microbiota and diabetes: From mechanisms to clinical application. *Nature Reviews Endocrinology*, 17(10), 615–632. <https://doi.org/10.1038/s41574-021-00507-0>
49. Knip, M., & Simell, O. (2012). Environmental triggers of type 1 diabetes. *Cold Spring Harbor Perspectives in Medicine*, 2(7), a007690. <https://doi.org/10.1101/cshperspect.a007690>
50. Van Belle, T. L., Coppieters, K. T., & von Herrath, M. G. (2011). Type 1 diabetes: Etiology, immunology, and therapeutic strategies. *Physiological Reviews*, 91(1), 79–118. <https://doi.org/10.1152/physrev.00003.2010>

51. Wenzlau, J. M., Juhl, K., Yu, L., Moua, O., Sarkar, S. A., Gottlieb, P., & Hutton, J. C. (2007). The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. *Proceedings of the National Academy of Sciences*, 104(43), 17040–17045. <https://doi.org/10.1073/pnas.0705894104>
52. Herold, K. C., Gitelman, S. E., Ehlers, M. R., Gottlieb, P. A., Greenbaum, C. J., Hagopian, W., & Bluestone, J. A. (2019). Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in new-onset type 1 diabetes in a randomized controlled trial. *Science Translational Medicine*, 11(484), eaaw0681. <https://doi.org/10.1126/scitranslmed.aaw0681>
53. Long, S. A., Rieck, M., Sanda, S., Bollyky, P. L., Samuels, P. L., Goland, R., & Buckner, J. H. (2012). Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. *Diabetes*, 61(9), 2340–2348. <https://doi.org/10.2337/db12-0049>
54. Fiorina, P., Vergani, A., Dada, S., Jurewicz, M., Wong, M., Law, K., & Sayegh, M. H. (2008). Targeting CD20+ B-cells restores T-cell homeostasis and insulin production in type 1 diabetes. *Diabetes*, 57(12), 3013–3024. <https://doi.org/10.2337/db08-0332>
55. Battaglia, M., Anderson, M. S., Buckner, J. H., Dotta, F., Ferrer, L., Piemonti, L., & Atkinson, M. A. (2017). Understanding and preventing type 1 diabetes through the unique working model of TrialNet. *Diabetes*, 66(5), 1153–1161. <https://doi.org/10.2337/db16-1215>
56. Ziegler, A. G., & Nepom, G. T. (2010). Prediction and pathogenesis in type 1 diabetes. *Immunity*, 32(4), 468–478. <https://doi.org/10.1016/j.immuni.2010.03.018>
57. Salama, R. A. A., Patni, M. A. M. F., Ba-Hutair, S. N. M., Wadid, N. A., & Akikwala, M. S. (2024). Exploring novel treatment modalities for Type 1 diabetes mellitus: Potential and prospects. *Healthcare*, 12(15), Article 1485. <https://doi.org/10.3390/healthcare12151485>
58. Martin, S., Wolf-Eichbaum, D., Duinkerken, G., Scherbaum, W. A., Kolb, H., Noordzij, J. G., & Roep, B. O. (2001). Development of type 1 diabetes despite severe hereditary B-cell deficiency. *New England Journal of Medicine*, 345(14), 1036-1040. <https://doi.org/10.1056/NEJMoa010465>
59. Garg, V. (2011). Noninsulin pharmacological management of Type 1 diabetes mellitus. *Indian Journal of Endocrinology and Metabolism*, 15(Suppl 1), S5–S11. <https://doi.org/10.4103/2230-8210.83053>
60. Wang, J., Shen, X., He, S., An, Y., Gong, Q., Li, H., & Li, G. (2019). Hypertriglyceridaemia predicts subsequent long-term risk of cardiovascular events in Chinese adults: 23-year follow-up of the Daqing Diabetes Study. *Diabetes/Metabolism Research and Reviews*, 35(6), e3163. <https://doi.org/10.1002/dmrr.3163>
61. Lan, N. S., Hong, R. S., Ryan, C., Jenkins, A. J., & Fegan, P. G. (2023). Patient perceptions of cardiovascular risk, lipid management and statins in type 1 diabetes. *Primary care diabetes*, 17(5), 526-528. <https://doi.org/10.1016/j.pcd.2023.07.005>
62. Najafipour, M., Najafipour, F., Ostadrahimi, A., Ghavami, M., Razaghi, Z., Tutunchi, H., & Alamdari, N. M. (2024). The effects of empagliflozin in patients with type 1 diabetes: Results of a 12-week, double-blind, randomized, placebo-controlled clinical trial. *Health Promotion Perspectives*, 14(4), 380-387. <https://doi.org/10.34172/hpp.42486>

63. Liu, Y., Yang, S., Jiang, A., Zou, D., Chen, Z., & Su, N. (2025). Risk of diabetic ketoacidosis caused by sodium glucose cotransporter-2 inhibitors in patients with type 1 diabetes: a systematic review and network meta-analysis of randomized controlled trials. *Frontiers in Endocrinology*, 15, 1453067. <https://doi.org/10.3389/fendo.2024.1453067>
64. Yau, C., & Danska, J. S. (2024). Cracking the type 1 diabetes code: Genes, microbes, immunity, and the early life environment. *Immunological Reviews*, 325(1), 23-45. <https://doi.org/10.1111/imr.13362>
65. Leão, I. S., Dantas, J. R., Araújo, D. B., Ramos, M. E. N., Silva, K. R., Batista, L. S., & Rodacki, M. (2024). Evaluation of type 1 diabetes' partial clinical remission after three years of heterologous adipose tissue derived stromal/stem cells transplantation associated with vitamin D supplementation. *Diabetology & Metabolic Syndrome*, 16(1), 114. <https://doi.org/10.1186/s13098-024-01302-2>
66. Millman, J. R., Xie, C., Van Dervort, A., Gürtler, M., Pagliuca, F. W., & Melton, D. A. (2016). Generation of stem cell-derived β -cells from patients with type 1 diabetes. *Nature Communications*, 7(1), 11463. <https://doi.org/10.1038/ncomms11463>
67. Hunault, L., & Hesselton, D. (2024). Finishing the odyssey to a stem cell cure for type 1 diabetes. *Metabolic Health and Disease*, 2(1), 9. <https://doi.org/10.1038/s44324-024-00014-5>
68. Wang, Y., Chen, Y., McGarrigle, J., Cook, J., Rios, P. D., La Monica, G., & Oberholzer, J. (2025). Cell Therapy for T1D Beyond BLA: Gearing Up Toward Clinical Practice. *Diabetes Therapy*, 1-14. <https://doi.org/10.1007/s13300-025-01732-9>
69. Murri, M., Leiva, I., Gomez-Zumaquero, J. M., Tinahones, F. J., Cardona, F., Soriguer, F., & Queipo-Ortuño, M. I. (2013). Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. *BioMed Central Medicine*, 11, 1-12. <https://doi.org/10.1186/1741-7015-11-46>
70. Marino, E., Richards, J. L., McLeod, K. H., Stanley, D., Yap, Y. A., Knight, J., & Mackay, C. R. (2017). Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. *Nature Immunology*, 18(5), 552-562. <https://doi.org/10.1038/ni.3713>
71. Vatanen, T., Franzosa, E. A., Schwager, R., Tripathi, S., Arthur, T. D., Vehik, K., & Xavier, R. J. (2018). The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. *Nature*, 562(7728), 589-594. <https://doi.org/10.1038/s41586-018-0620-2>
72. Wszola, M., Nitarska, D., Cywoniuk, P., Gomółka, M., & Klak, M. (2021). Stem cells as a source of pancreatic cells for production of 3D bioprinted bionic pancreas in the treatment of type 1 diabetes. *Cells*, 10(6), 1544. <https://doi.org/10.3390/cells10061544>
73. Antonio-Villa, N. E., García-Tuomola, A., Almeda-Valdes, P., Vidrio-Velázquez, M., Islas-Ortega, L., Madrigal-Sanromán, J. R., & RENACED-DT1 Research Group. (2021). Glycemic control, treatment and complications in patients with type 1 diabetes amongst healthcare settings in Mexico. *Diabetes Research and clinical practice*, 180, 109038. <https://doi.org/10.1016/j.diabres.2021.109038>

74. Zhang, Q., Gonelle-Gispert, C., Li, Y., Geng, Z., Gerber-Lemaire, S., Wang, Y., & Buhler, L. (2022). Islet encapsulation: new developments for the treatment of type 1 diabetes. *Frontiers in Immunology*, 13, 869984. <https://doi.org/10.3389/fimmu.2022.869984>
75. Monami, M., Nreu, B., Zannoni, S., Lualdi, C., & Mannucci, E. (2017). Effects of SGLT-2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials. *Diabetes Research and Clinical Practice*, 130, 53-60. <https://doi.org/10.1016/j.diabres.2017.04.017>
76. Mathieu, C., Rudofsky, G., Phillip, M., Araki, E., Lind, M., Arya, N., & Dandona, P. (2020). Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial. *Diabetes, Obesity and Metabolism*, 22(9), 1516-1526. <https://doi.org/10.1111/dom.14060>
77. Bjornstad, P., Schäfer, M., Truong, U., Cree-Green, M., Pyle, L., Baumgartner, A., & Nadeau, K. J. (2018). Metformin improves insulin sensitivity and vascular health in youth with type 1 diabetes mellitus: randomized controlled trial. *Circulation*, 138(25), 2895-2907. <https://doi.org/10.1161/CIRCULATIONAHA.118.035525>
78. Araki, E., Mathieu, C., Shiraiwa, T., Maeda, H., Ikeda, H., Thoren, F., & Iqbal, N. (2021). Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study. *Diabetes, Obesity and Metabolism*, 23(7), 1496-1504. <https://doi.org/10.1111/dom.14362>
79. Ma, J., Zhao, Y., Fan, H., & Liu, J. (2021). The efficacy of dapagliflozin for type 1 diabetes: a meta-analysis of randomized controlled studies. *African Health Sciences*, 21(1), 1-7. <https://doi.org/10.4314/ahs.v21i1.2>
80. Lund, S. S., Tarnow, L., Astrup, A. S., Hovind, P., Jacobsen, P. K., Alibegovic, A. C., Parving, I., Pietraszek, L., Frandsen, M., Rossing, P., Parving, H. H., & Vaag, A. A. (2008). Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. *Public Library of Science ONE*, 3(10), e3363. <https://doi.org/10.1371/journal.pone.0003363>
81. Lacigova, S., Rusavý, Z., Jankovec, Z., & Kyselova, P. (2001). Metformin in the treatment of type 1 diabetics--a placebo controlled study. *Casopis Lekaru Ceskych*, 140(10), 302-306. PMID: 11411059.
82. Scaramuzza, A., Giani, E., Redaelli, F., Ungheri, S., Macedoni, M., Giudici, V., Bosetti, A., Ferrari, M., & Zuccotti, G. V. (2015). Alpha-Lipoic Acid and Antioxidant Diet Help to Improve Endothelial Dysfunction in Adolescents with Type 1 Diabetes: A Pilot Trial. *Journal of Diabetes Research*, 2015, 474561. <https://doi.org/10.1155/2015/474561>
83. Ding, Q., Sun, B., Wang, M., Li, T., Li, H., Han, Q., & Tang, Z. (2023). N-acetylcysteine alleviates oxidative stress and apoptosis and prevents skeletal muscle atrophy in type 1 diabetes mellitus through the NRF2/HO-1 pathway. *Life Sciences*, 329, 121975. <https://doi.org/10.1016/j.lfs.2023.121975>
84. Musso, G., Sircana, A., Saba, F., Cassader, M., & Gambino, R. (2020). Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: a meta-analysis and meta-regression. *Public Library of Science ONE medicine*, 17(12), e1003461. <https://doi.org/10.1371/journal.pmed.1003461>

85. Danne, T., Garg, S., Peters, A. L., Buse, J. B., Mathieu, C., Pettus, J. H., & Phillip, M. (2019). International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium–glucose cotransporter (SGLT) inhibitors. *Diabetes Care*, 42(6), 1147-1154. <https://doi.org/10.2337/dc18-2316>
86. Holt, R. I., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., & Peters, A. L. (2021). The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, 44(11), 2589-2625. <https://doi.org/10.2337/dci21-0043>
87. Butrym, M., Byvald, F., Blanter, M., Ringqvist, E. E., Vasylovska, S., Marjomäki, V., & Flodström-Tullberg, M. (2024). Vemurafenib inhibits the replication of diabetogenic enteroviruses in intestinal epithelial and pancreatic beta cells. *Antiviral Research*, 231, 106021. <https://doi.org/10.1016/j.antiviral.2024.105527>
88. Roy, S., Pokharel, P., & Piganelli, J. D. (2024). Decoding the immune dance: Unraveling the interplay between beta cells and type 1 diabetes. *Molecular Metabolism*, 101998. <https://doi.org/10.1016/j.molmet.2024.101826>
89. Collins, J., & Farnsworth, N. L. (2025). Active targeting of type 1 diabetes therapies to pancreatic beta cells using nanocarriers. *Diabetologia*, 1-12. <https://doi.org/10.1007/s00125-024-06356-5>
90. Keymeulen, B., van Maurik, A., Inman, D., Oliveira, J., McLaughlin, R., Gittelman, R. M., & Napolitano, A. (2021). A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody oteelixumab in new-onset type 1 diabetes. *Diabetologia*, 64, 313-324. <https://doi.org/10.1007/s00125-020-05317-y>
91. Kokori, E., Olatunji, G., Ogieuhi, I. J., Aboje, J. E., Olatunji, D., Aremu, S. A., & Aderinto, N. (2024). Teplizumab's immunomodulatory effects on pancreatic β -cell function in type 1 diabetes mellitus. *Clinical Diabetes and Endocrinology*, 10(1), 23. <https://doi.org/10.1186/s40842-024-00181-w>
92. Tauschmann, M., & Hovorka, R. (2018). Technology in the management of type 1 diabetes mellitus—current status and future prospects. *Nature Reviews Endocrinology*, 14(8), 464-475. <https://doi.org/10.1038/s41574-018-0044-y>
93. Santos, A. S., Cunha Neto, E., Fukui, R. T., Ferreira, L. R., & Silva, M. E. R. (2019). Increased expression of circulating microRNA 101-3p in type 1 diabetes patients: new insights into miRNA-regulated pathophysiological pathways for type 1 diabetes. *Frontiers in Immunology*, 10, 1637. <https://doi.org/10.3389/fimmu.2019.01637>
94. Cherney, D. Z., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., & von Eynatten, M. (2014). Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. *Circulation*, 129(5), 587-597. <https://doi.org/10.1161/CIRCULATIONAHA.113.005081>
95. Hogrebe, N. J., Ishahak, M., & Millman, J. R. (2023). Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes. *Cell stem cell*, 30(5), 530–548. <https://doi.org/10.1016/j.stem.2023.04.002>

96. Steffes, M. W., Chavers, B. M., Molitch, M. E., Cleary, P. A., Lachin, J. M., Genuth, S., & Nathan, D. M. (2003). Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. *JAMA: Journal of the American Medical Association*, 290(16). <https://doi.org/10.1001/jama.290.16.2159>
97. Atkinson, M. A., & Eisenbarth, G. S. (2001). Type 1 diabetes: new perspectives on disease pathogenesis and treatment. *Lancet (London, England)*, 358(9277), 221–229. [https://doi.org/10.1016/S0140-6736\(01\)05415-0](https://doi.org/10.1016/S0140-6736(01)05415-0)
98. Boeder, S., & Edelman, S. V. (2019). Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials. *Diabetes, Obesity and Metabolism*, 21, 62–77. <https://doi.org/10.1111/dom.13749>
99. Boeder, S. C., Thomas, R. L., Le Roux, M. J., Giovannetti, E. R., Gregory, J. M., & Pettus, J. H. (2025). Combination SGLT2 Inhibitor and Glucagon Receptor Antagonist Therapy in Type 1 Diabetes: A Randomized Clinical Trial. *Diabetes care*, 48(1), 52–60. <https://doi.org/10.2337/dc24-0212>
100. Mesples, A., Majeed, N., Zhang, Y., & Hu, X. (2013). Early immunotherapy using autologous adult stem cells reversed the effect of anti-pancreatic islets in recently diagnosed type 1 diabetes mellitus: preliminary results. *Medical science monitor: International Medical Journal of Experimental and Clinical Research*, 19, 852–857. <https://doi.org/10.12659/MSM.889525>
101. Zhao, Y., Lin, B., Darflinger, R., Zhang, Y., Holterman, M. J., & Skidgel, R. A. (2009). Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice. *Public Library of Science ONE*, 4(1), e4226. <https://doi.org/10.1371/journal.pone.0004226>
102. Gubitosi-Klug, R. A., Lachin, J. M., Backlund, J. Y. C., Lorenzi, G. M., Brillon, D. J., Orchard, T. J., & Diabetes Control and Complications Trial (DCCT. (2016). Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. *Diabetes Care*, 39(5). <https://doi.org/10.2337/dc15-1990>
103. George, P., & 1 diabetes. McCrimmon, R. J. (2013). Potential role of non-insulin adjunct therapy in Type Diabetic medicin: *A Journal of the British Diabetic Association*, 30(2), 179–188. <https://doi.org/10.1111/j.1464-5491.2012.03744.x>